Pharmaceutical Market Sweden
What is the pharmaceutical research & development environment like in Sweden?
Sweden’s strength in research & development bodes well for the future of the biologic sector.
Principal research & development areas within the Swedish pharmaceutical market include oncology, gastrointestinal disorders, respiratory diseases, cardiovascular diseases and metabolic diseases. Around 5,000 people are employed in R&D in Sweden, equal to almost one third of the industry workforce.
The combined clinical research expenditure of LIF member companies totalled SEK5.5 billion (US$0.7 billion) in 2009, when there were 187 clinical trials underway, of which 99 were in Phase III of development. The trials involved a total of around 5,500 patients.
There are a number of small biologic companies in Sweden, as well as several multinationals which engage in biopharmaceutical R&D and production. In 2011, a total of 63 biotechnology R&D projects are under development at 35 companies. This excludes projects at AstraZeneca, which has around 40% of its global R&D workforce based in Sweden. The most popular therapeutic category within the Swedish drug development pipeline is cancer, followed by the central nervous system and infection. The strength of R&D in Sweden bodes well for the future of the biotechnology industry.
To find out more please click on the link below;